Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation

Acta Haematologica

Volumn 132, Issue 2, 2014, Pages 211-219

  Ozaki, Shuji ^a   Harada, Takeshi ^b   Saitoh, Takayuki ^c   Shimazaki, Chihiro ^d   Itagaki, Mitsuhiro ^e   Asaoku, Hideki ^e   Kuroda, Yoshiaki ^f   Chou, Takaaki ^g   Yoshiki, Yumiko ^h   Suzuki, Kenshi ^h   Murakami, Hirokazu ^c   Hayashi, Kunihiko ^c   Mina, Roberto ^j   Palumbo, Antonio ^j   Shimizu, Kazuyuki ⁱ  

^a TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d Department of Basic Medical Sciences Gunma University Graduate School of Health Sciences ^*  (Japan)

^e ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^f HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^g NIIGATA CANCER CENTER HOSPITAL   (Japan)

^h JAPANESE RED CROSS MEDICAL CENTER   (Japan)

ⁱ Japanese Society of Myeloma   (Japan)

^j UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

Autologous stem cell transplantation; Bortezomib; Immunomodulatory drugs; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; THALIDOMIDE; VINCRISTINE; ANGIOGENESIS INHIBITOR; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; NEW DRUG; PROTEIN KINASE INHIBITOR; PYRAZINE DERIVATIVE;

AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME; CANCER CHEMOTHERAPY; CLINICAL FEATURE; SURVIVAL RATE; SURVIVAL TIME; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; EUROPE; JAPAN; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUGS, INVESTIGATIONAL; EUROPE; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PYRAZINES; RETROSPECTIVE STUDIES; SALVAGE THERAPY; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84896432926     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000357394     Document Type: Article

References (18)

1. Palumbo A, Anderson K: Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA: Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
3. Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, Garcia-Larana J, Sureda A, de la Rubia J, Conde E, Martinez R, de Arriba F, Viguria MC, Besalduch J, Cabrera R, Gonzalez-San Miguel JD, Guzman-Zamudio JL, Gomez del Castillo MC, Moraleda JM, Garcia-Ruiz JC, San Miguel J, Lahuerta JJ; Grupo Espanol de MM; Programa para el Estudio de la Terape utica en Hemopatia M: Long-Term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011; 118: 529-534.
4. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, Romano A, Liberati AM, Siniscalchi A, Petrucci MT, Nozzoli C, Patriarca F, Offidani M, Ria R, Omede P, Bruno B, Passera R, Musto P, Boccadoro M, Sonneveld P, Palumbo A: Complete response correlates with long-Term progression-free and overall survival in elderly myeloma treated with novel agents: Analysis of 1,175 patients. Blood 2011; 117: 3025-3031.
5. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F: Multiple myeloma. J Natl Compr Canc Netw 2011; 9: 1146-1183.
6. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R: Multiple myeloma, version 1.2013. J Natl Compr Canc Netw 2013; 11: 11-17.
7. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, Omede P, Tarella C, Pileri A, Boccadoro M: Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248-1253.
8. Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA: Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol 2008; 83: 614-617.
9. Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M: Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 2010; 28: 800-807.
10. Durie BG, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
11. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J: International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
12. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV: International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
13. Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, Narimatsu H, Fujii T, Kawabata M, Taniguchi S, Ozawa K, Oshimi K: Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006; 107: 3492-3494.
14. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 1998; 16: 3832-3842.
15. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621-4629.
16. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M, Network GIM: Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. Lancet 2010; 376: 2075-2085.
17. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM: Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946-2955.
18. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.